Meek, whose future was unclear after FerGene melted down in spectacular fashion earlier this year and ousted its leadership team, will take over a Mirati outfit with a lead KRAS inhibitor prepping for an FDA filing in Q4. The company rolled out Phase II data for adagrasib in non-small cell lung cancer earlier Monday morning that it says will serve as the basis for that filing, as well as winning mid-stage colon cancer data at this weekend’s #ESMO21.
Back in late 2019, FerGene looked golden. It had a gene therapy for bladder cancer — spun out of Ferring — at the FDA, with a priority review and breakthrough status indicating that great things awaited on the near horizon.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--FerGene, Inc., a privately held gene therapy company dedicated to revolutionizing the treatment of bladder cancer, today announced the appointment of top biotech leaders to its executive team. The newly appointed leaders bring a wealth of experience and proven track records of success in oncology and urology to the company, as FerGene prepares to potentially commercialize the first gene therapy for patients living with non-muscle invasive bladder cancer (NMIBC) in the U.S.
Data highlight a need for bladder-sparing therapies to improve outcomes for patients with high-grade, non-muscle invasive bladder cancer
Data highlight a need for bladder-sparing therapies to improve outcomes for patients with high-grade, non-muscle invasive bladder cancer
A new gene therapy spinout has nabbed Ipsen chief executive David Meek to help sell its new drug.
EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the efficacy and safety data from the REVERSE-SD clinical study were presented at the Clinical Trials in Alzheimer's Disease (CTAD) meeting in San Diego by the principal investigator of the study, Professor Philip Scheltens of the VU Medical Center in Amsterdam, Netherlands.